Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Effect of a task-oriented rehabilitation program on upper extremity recovery following motor stroke: the ICARE randomized clinical trial
Winstein CJ, Wolf SL, Dromerick AW, Lane CJ, Nelsen MA, Lewthwaite R, Cen SY, Azen SP, for the Interdisciplinary Comprehensive Arm Rehabilitation Evaluation (ICARE) Investigative Team
JAMA 2016 Feb 9;315(6):571-581
clinical trial
6/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: No; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: No; Adequate follow-up: Yes; Intention-to-treat analysis: Yes; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*

IMPORTANCE: Clinical trials suggest that higher doses of task-oriented training are superior to current clinical practice for patients with stroke with upper extremity motor deficits. OBJECTIVE: To compare the efficacy of a structured, task-oriented motor training program versus usual and customary occupational therapy (UCC) during stroke rehabilitation. DESIGN, SETTING, AND PARTICIPANTS: Phase 3, pragmatic, single-blind randomized trial among 361 participants with moderate motor impairment recruited from 7 US hospitals over 44 months, treated in the outpatient setting from June 2009 to March 2014. INTERVENTIONS: Structured, task-oriented upper extremity training (Accelerated Skill Acquisition Program (ASAP); n = 119); dose-equivalent occupational therapy (DEUCC; n = 120); or monitoring-only occupational therapy (UCC; n = 122). The DEUCC group was prescribed 30 one-hour sessions over 10 weeks; the UCC group was only monitored, without specification of dose. MAIN OUTCOMES AND MEASURES: The primary outcome was 12-month change in log-transformed Wolf Motor Function Test time score (WMFT, consisting of a mean of 15 timed arm movements and hand dexterity tasks). Secondary outcomes were change in WMFT time score (minimal clinically important difference (MCID) = 19 seconds) and proportion of patients improving >= v25 points on the Stroke Impact Scale (SIS) hand function score (MCID 17.8 points). RESULTS: Among the 361 randomized patients (mean age, 60.7 years; 56% men; 42% African American; mean time since stroke onset, 46 days), 304 (84%) completed the 12-month primary outcome assessment; in intention-to-treat analysis, mean group change scores (log WMFT, baseline to 12 months) were, for the ASAP group 2.2 to 1.4 (difference 0.82); DEUCC group 2.0 to 1.2 (difference 0.84); and UCC group 2.1 to 1.4 (difference 0.75), with no significant between-group differences (ASAP versus DEUCC 0.14; 95% CI -0.05 to 0.33; p = 0.16; ASAP versus UCC -0.01; 95% CI -0.22 to 0.21; p = 0.94; and DEUCC versus UCC -0.14; 95% CI -0.32 to 0.05; p = 0.15). Secondary outcomes for the ASAP group were WMFT change score -8.8 seconds, and improved SIS 73%; DEUCC group WMFT -8.1 seconds, and SIS 72%; and UCC group WMFT -7.2 seconds, and SIS 69%, with no significant pairwise between-group differences (ASAP versus DEUCC WMFT 1.8 seconds; 95% CI -0.8 to 4.5 seconds; p = 0.18; improved SIS 1%; 95% CI -12% to 13%; p = 0.54; ASAP versus UCC WMFT -0.6 seconds, 95% CI -3.8 to 2.6 seconds; p = 0.72; improved SIS 4%; 95% CI -9% to 16%; p = 0.48; and DEUCC versus UCC WMFT -2.1 seconds; 95% CI -4.5 to 0.3 seconds; p = 0.08; improved SIS 3%; 95% CI -9% to 15%; p = 0.22). A total of 168 serious adverse events occurred in 109 participants, resulting in 8 patients withdrawing from the study. CONCLUSIONS AND RELEVANCE: Among patients with motor stroke and primarily moderate upper extremity impairment, use of a structured, task-oriented rehabilitation program did not significantly improve motor function or recovery beyond either an equivalent or a lower dose of UCC upper extremity rehabilitation. These findings do not support superiority of this program among patients with motor stroke and primarily moderate upper extremity impairment. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT00871715.

Full text (sometimes free) may be available at these link(s):      help